NANCY HAM - 12 Jun 2025 Form 4 Insider Report for U S PHYSICAL THERAPY INC /NV (USPH)

Role: Director
Signature: /s/ Kate Venturina, as attorney-in-fact
Issuer symbol: USPH
Transactions as of: 12 Jun 2025
Net transactions value: -$31,204
Form type: 4
Filing time: 13 Jun 2025, 16:30:11 UTC
Previous filing: 21 May 2025
Next filing: 11 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
HAM NANCY	Director	1300 W SAM HOUSTON PKWY S, SUITE 300, HOUSTON	/s/ Kate Venturina, as attorney-in-fact	13 Jun 2025	0001124500

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	USPH	Common Stock	Sale	$31,204	-400	-13%	$78.01	2,594	12 Jun 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is weighted average price ($78.01). The shares were sold in multiple transactions at prices ranging from $77.99 to $78.03 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2	Includes 1,882 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 941 shares on August 20, 2025, 470 shares on November 20, 2025, and 471 shares on March 6, 2026, if she is a director of the Company on those dates.

Content

The price reported is weighted average price ($78.01). The shares were sold in multiple transactions at prices ranging from $77.99 to $78.03 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Includes 1,882 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 941 shares on August 20, 2025, 470 shares on November 20, 2025, and 471 shares on March 6, 2026, if she is a director of the Company on those dates.